Investor Relations

2017 Press Releases

Keyword Search
 
Categories: 
All | Financial
Select Year:
2017 | 2016 | 2015 | 2014 | 2013
DateTitle 
11/10/17MediciNova Appoints Hideki Nagao to its Board of DirectorsPrinter Friendly Version
11/09/17MediciNova Announces Collaboration with the U.S. Department of Veterans Affairs and Oregon Health & Science University to Evaluate MN-166 (ibudilast) in Methamphetamine Use DisorderPrinter Friendly Version
11/01/17MediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted for Presentation at the 28th International Symposium on ALS/MND in Boston, MA, USAPrinter Friendly Version
10/30/17MediciNova Announces the Presentation of Additional Positive Top-Line Results from the SPRINT-MS Phase 2b Trial of MN-166 (ibudilast) in Progressive MS:  Achieved a Statistically Significant 48% Reduction in Whole Brain Atrophy with a Favorable Safety and Tolerability ProfilePrinter Friendly Version
10/26/17MediciNova Announces Positive Top-Line Results from the SPRINT-MS Phase 2b Trial of MN-166 (ibudilast) in Progressive MS:  Achieved Both Primary Endpoints including a Significant Reduction in Whole Brain Atrophy and Safety and TolerabilityPrinter Friendly Version
09/19/17MediciNova Announces the Completion of Enrollment in the Phase 2 Clinical Trial of MN-166 (ibudilast) in Methamphetamine DependencePrinter Friendly Version
09/18/17MediciNova to Present at the Ladenburg Thalmann 2017 Healthcare Conference in New YorkPrinter Friendly Version
08/30/17MediciNova Announces the Abstract from the MN-166 (ibudilast) SPRINT-MS Phase 2b Study in Progressive MS - including Top Line Data - was Selected as a Platform Presentation for Late-Breaking Presentation at the 7th Joint ECTRIMS - ACTRIMS Meeting on October 28, 2017 in Paris, FrancePrinter Friendly Version
06/05/17MediciNova Announces Positive Results from a Glioblastoma Animal Model Study Presented at the 2017 American Society of Clinical Oncology Annual Meeting in Chicago, IllinoisPrinter Friendly Version
04/25/17MediciNova Announces Exploratory Interim Clinical Outcomes Data from Clinical Trial of MN-166 (ibudilast) in ALS Presented at the American Academy of Neurology (AAN) 69th Annual Meeting  in BostonPrinter Friendly Version
04/09/17MediciNova Announces MN-166 (ibudilast) Glioblastoma Abstract Selected for Presentation at the 2017 American Society of Clinical Oncology Annual Meeting in Chicago, IllinoisPrinter Friendly Version
02/27/17MediciNova Announces MN-166 (ibudilast) Glioblastoma Abstract Selected for Presentation at the 5th Quadrennial Meeting of the World Federation of Neuro-Oncology Societies in Zurich, SwitzerlandPrinter Friendly Version
02/07/17MediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted for Presentation at the American Academy of Neurology (AAN) 69th Annual Meeting in BostonPrinter Friendly Version
02/06/17MediciNova Announces Positive Findings from Completed Trial of MN-166 (ibudilast) in Methamphetamine Dependence Presented at the 50th Winter Conference on Brain ResearchPrinter Friendly Version
02/01/17MediciNova to Attend Mizuho Healthcare Conference in New YorkPrinter Friendly Version
01/23/17MediciNova Announces Publication of Positive Findings on MN-166 (ibudilast) in Alcohol DependencePrinter Friendly Version